The model-adjusted treatment difference of 0.11 % ( 95 % CI -0.04 % , 0.27 % ) ( 1.2 mmol/mol [ 95 % CI -0.4 , 3.0 mmol/mol ] ) indicated non-inferiority of albiglutide to insulin glargine based on the pre-specified non-inferiority margin of 0.3 % ( 3.3 mmol/mol , p = 0.0086 ) .
